Alectinib

Alectinib
Clinical data
Pronunciation	/əˈlɛktɪnɪb/ ə-LEK-ti-nib
Trade names	Alecensa
Other names	alectinib hydrochloride (JAN JP)
AHFS/Drugs.com	Monograph
MedlinePlus	a616007
License data	US DailyMed: Alectinib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01ED03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	37% (under fed conditions)
Protein binding	>99%
Metabolism	Mainly CYP3A4
Metabolites	M4 (active)
Elimination half-life	33 hours (alectinib), 31 hours (M4)
Excretion	Feces (98%)
Identifiers
	IUPAC name 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile;
CAS Number	1256580-46-7; as HCl: 1256589-74-8;
PubChem CID	49806720;
DrugBank	DB11363;
ChemSpider	26326738;
UNII	LIJ4CT1Z3Y; as HCl: P9YY73LO6J;
KEGG	D10542; as HCl: D10450;
ChEBI	CHEBI:90936;
CompTox Dashboard (EPA)	DTXSID50154840 ;
ECHA InfoCard	100.256.083
Chemical and physical data
Formula	C30H34N4O2
Molar mass	482.628 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C;
	InChI InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3 COPY; Key:KDGFLJKFZUIJMX-UHFFFAOYSA-N; Key:GYABBVHSRIHYJR-UHFFFAOYSA-N;

Alectinib (INN,), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC). It blocks the activity of anaplastic lymphoma kinase (ALK). It is taken by mouth. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.

The most common side effects include constipation, muscle pain and edema (swelling) including of the ankles and feet, the face, the eyelids and the area around the eyes.

Alectinib was approved for medical use in Japan in 2014, the United States in 2015, Canada in 2016, Australia in 2017, the European Union in 2017, and the United Kingdom in 2021.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.